Anthem Biosciences Ltd Sees Technical Momentum Shift Amid Strong Price Gains

Technical Momentum Shift: From Mildly Bearish to Mildly Bullish

Recent technical analysis reveals that Anthem Biosciences has transitioned from a mildly bearish stance to a mildly bullish one on weekly charts. This shift is underpinned by several key indicators. The Moving Average Convergence Divergence (MACD) on the weekly timeframe has turned mildly bullish, indicating increasing upward momentum. Although the monthly MACD remains neutral, the weekly signal is often a precursor to longer-term trend changes.

The Relative Strength Index (RSI) on the weekly chart currently shows no definitive signal, hovering in a neutral zone. This suggests that while the stock is not yet overbought or oversold, there is room for further upward movement without immediate risk of a reversal due to overextension.

Bollinger Bands on the weekly scale have turned bullish, reflecting increased volatility with a positive price breakout above the middle band. This technical behaviour often precedes sustained price rallies, as the stock price moves towards the upper band, signalling strength.

Moving Averages and Dow Theory Confirm Mild Bullishness

Daily moving averages, while not explicitly detailed, appear to support the emerging bullish momentum, as the stock price has risen from a previous close of ₹689.85 to a high of ₹730.35 during the trading session. The Dow Theory analysis corroborates this trend, with both weekly and monthly readings indicating a mildly bullish outlook. This dual confirmation across timeframes adds credibility to the positive momentum narrative.

However, the On-Balance Volume (OBV) indicator on the weekly chart remains bearish, suggesting that volume trends have yet to fully confirm the price strength. The monthly OBV shows no clear trend, indicating that investor participation in the rally is still tentative. This divergence between price action and volume warrants cautious optimism.

Price Performance Relative to Benchmarks

Anthem Biosciences’ recent price action has outperformed the broader market benchmark, the Sensex, across multiple time horizons. Over the past week, the stock has delivered a robust 9.3% return compared to the Sensex’s 4.52%. This outperformance extends to the monthly period, with Anthem gaining 9.5% while the Sensex declined by 1.2%. Year-to-date, the stock has appreciated by 11.01%, contrasting sharply with the Sensex’s negative 10.08% return.

These figures highlight the stock’s relative strength amid a challenging market environment, underscoring its potential as a sector-specific outperformer. The 52-week price range of ₹579.45 to ₹873.25 further contextualises the current price level of ₹722.70, which sits comfortably above the midpoint, suggesting room for further appreciation.

Mojo Score and Grade Update: A Cautious Sell Recommendation

MarketsMOJO has recently downgraded Anthem Biosciences from a Hold to a Sell rating as of 6 April 2026, reflecting a Mojo Score of 40.0. This score places the stock in the lower quartile of its peer group within the Pharmaceuticals & Biotechnology sector. The downgrade signals concerns over the stock’s medium-term fundamentals and risk profile despite the recent technical improvements.

The mid-cap classification of Anthem Biosciences means it is subject to higher volatility compared to large-cap peers, which may explain the mixed signals from volume-based indicators like OBV. Investors should weigh the technical momentum against the fundamental caution advised by the Mojo Grade.

Sector Context and Industry Positioning

Within the Pharmaceuticals & Biotechnology sector, Anthem Biosciences operates in a competitive and innovation-driven environment. The sector itself has experienced mixed performance, with some companies benefiting from recent regulatory approvals and others facing pricing pressures. Anthem’s recent price momentum may be partially attributed to sector rotation favouring mid-cap biotech firms with promising pipelines.

However, the lack of strong volume confirmation and the cautious Mojo Grade suggest that investors should monitor upcoming earnings and pipeline developments closely before committing to a long position.

Price Volatility and Trading Range

On 10 April 2026, the stock traded within a range of ₹690.70 to ₹730.35, demonstrating intraday volatility of approximately 5.7%. This range reflects active trading interest and potential profit-taking near the upper end of the 52-week range. The previous close of ₹689.85 indicates a strong gap-up opening, which often signals renewed buying interest.

Investors should note that the stock remains below its 52-week high of ₹873.25, suggesting that while momentum is improving, there is still a significant gap to previous peak levels. This gap may act as resistance in the near term.

Outlook and Investor Considerations

In summary, Anthem Biosciences Ltd is exhibiting early signs of a technical rebound, supported by weekly MACD and Bollinger Bands turning bullish, and Dow Theory confirming a mild uptrend. The stock’s recent outperformance relative to the Sensex and sector peers adds to the positive momentum narrative.

Nevertheless, the bearish weekly OBV and the recent downgrade to a Sell rating by MarketsMOJO counsel prudence. Investors should consider the stock’s volatility, mid-cap risk profile, and the absence of strong volume confirmation before increasing exposure.

For those with a higher risk tolerance, the current technical signals may offer an entry point to capitalise on a potential recovery. Conversely, more conservative investors might await further confirmation through volume trends and fundamental catalysts such as earnings or regulatory updates.

Given the mixed signals, a balanced approach combining technical monitoring with fundamental analysis is advisable for navigating Anthem Biosciences’ evolving market dynamics.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today